Bacterial infections represent a rapidly growing challenge to human health. Aminoglycosides are widely used broad-spectrum antibiotics, but they inflict permanent hearing loss in up to ~50% of patients by causing selective sensory hair cell loss. Here, we hypothesized that reducing aminoglycoside entry into hair cells via mechanotransducer channels would reduce ototoxicity, and therefore we synthesized 9 aminoglycosides with modifications based on biophysical properties of the hair cell mechanotransducer channel and interactions between aminoglycosides and the bacterial ribosome. Compared with the parent aminoglycoside sisomicin, all 9 derivatives displayed no or reduced ototoxicity, with the lead compound N1MS 17 times less ototoxic and with reduced penetration of hair cell mechanotransducer channels in rat cochlear cultures. Both N1MS and sisomicin suppressed growth of *E. coli* and *K. pneumoniae*, with N1MS exhibiting superior activity against extended spectrum β-lactamase producers, despite diminished activity against *P. aeruginosa* and *S. aureus*. Moreover, systemic sisomicin treatment of mice resulted in 75% to 85% hair cell loss and profound hearing loss, whereas N1MS treatment preserved both hair cells and hearing. Finally, in mice with *E. coli*-infected bladders, systemic N1MS treatment eliminated bacteria from urinary tract tissues and serially collected urine samples, without compromising auditory and kidney functions. Together, our findings establish N1MS as a nonototoxic aminoglycoside and support targeted modification as a promising approach to generating nonototoxic antibiotics.
Designer aminoglycosides prevent cochlear hair cell loss and hearing loss


Department of Otolaryngology – Head and Neck Surgery, Department of Urology, Department of Pediatrics, and Department of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, California, USA.

Bacterial infections represent a rapidly growing challenge to human health. Aminoglycosides are widely used broad-spectrum antibiotics, but they inflict permanent hearing loss in up to ~50% of patients by causing selective sensory hair cell loss. Here, we hypothesized that reducing aminoglycoside entry into hair cells via mechanotransducer channels would reduce ototoxicity, and therefore we synthesized 9 aminoglycosides with modifications based on biophysical properties of the hair cell mechanotransducer channel and interactions between aminoglycosides and the bacterial ribosome. Compared with the parent aminoglycoside sisomicin, all 9 derivatives displayed no or reduced ototoxicity, with the lead compound N1MS 17 times less ototoxic and with reduced penetration of hair cell mechanotransducer channels in rat cochlear cultures. Both N1MS and sisomicin suppressed growth of E. coli and K. pneumoniae, with N1MS exhibiting superior activity against extended spectrum β-lactamase producers, despite diminished activity against P. aeruginosa and S. aureus. Moreover, systemic sisomicin treatment of mice resulted in 75% to 85% hair cell loss and profound hearing loss, whereas N1MS treatment preserved both hair cells and hearing. Finally, in mice with E. coli–infected bladders, systemic N1MS treatment eliminated bacteria from urinary tract tissues and serially collected urine samples, without compromising auditory and kidney functions. Together, our findings establish N1MS as a nonototoxic aminoglycoside and support targeted modification as a promising approach to generating nonototoxic antibiotics.

Introduction

Bacterial infections commonly overwhelm host defenses and require antimicrobial therapy. For over twenty years and despite newer alternative antibiotics, aminoglycosides remain the mainstay treatment worldwide for numerous disease entities, including pneumonia, peritonitis, sepsis, and genitourinary tract infection (1, 2). The salient features of aminoglycosides include potent antimicrobial activities and minimal drug-related allergies. On the other hand, their major limiting side effects are nephrotoxicity, loss of vestibular function, and permanent hearing impairment, which is detected in approximately 20% of treated patients using conventional audiometry (3, 4). When higher frequency hearing is examined, hearing loss is found in almost half of treated patients (47%) (5). This prevalence may be even higher at longer periods after treatment when considering the prolonged half-life of drug in the inner ear cochlea and the irreversible nature of cochlear hair cell loss (6). Despite these side effects, the World Health Organization recommends aminoglycosides as critically important antimicrobials for clinical use (7). At present, aminoglycoside-induced hearing loss represents one of the most common iatrogenic and preventable forms of hearing loss.

Results

Novel aminoglycoside derivatives exhibit decreased ototoxicity in vitro. Electrochemical gradients drive cations through the hair cell MET channels (Figure 1A and ref. 24). Although the molecular nature of this channel remains controversial, a significant body of literature exists on the biophysical properties (24, 26–30). Given that aminoglycosides are permeable blockers of the MET channel, we hypothesized that targeted modification to reduce positively charged sites on the aminoglycoside molecule would hinder drug entry into hair cells and thus prevent ototoxicity (9). Using established synthetic methods (31), we first chemically protected 3 of the amine groups on the aminoglycoside sisomicin, a biosynthetic precursor of gentamicin, thus allowing subsequent modification of the N1 and/or N3’ amine site (Supplemental Figure 1, A and B; supplemental material available online with this article; doi:10.1172/JCI77424DS1). Sisomicin was selected because it is hair cell MET channel is required for drug toxicity (9, 20–23), we have redesigned and modified the aminoglycoside sisomicin based on the biophysical properties of the hair cell MET channels (24) and aminoglycoside-bacterial ribosome interactions (25). Here, we have characterized 9 sisomicin derivatives with diminished ototoxicity in vitro, with 3 of the 9 compounds exhibiting comparable anti-E. coli activities to the parent compound sisomicin. The lead compound, N1MS, showed reduced permeation of the MET channel, likely due to the reduced charge per molecule of N1MS. In a mouse model of aminoglycoside-induced deafness, N1MS was significantly less ototoxic than sisomicin. Finally, N1MS treatment eliminated urinary tract infection in vivo. Collectively, our study characterizes a novel nonototoxic aminoglycoside and also introduces an approach to modifying existing aminoglycosides that can reduce ototoxicity while retaining antimicrobial activity.

Figure 1. Novel aminoglycosides have diminished ototoxicity in vitro. (A) Schematic showing that the nonselective hair cell MET channels are permeable to cations (calcium and aminoglycosides). (B) The sisomicin compound is comprised of 3 rings. Targeted modifications were made to the amine groups on the second (N1) and third rings (N3’). Three distinct chemical moieties were used to modify sisomicin: MS, PS, and BZ. N1BZ: R1=BZ, R2=H; N1MS: R1=MS, R2=H; N1PS: R1=PS, R2=H; N1,3”BZ: R1=BZ, R2=Z; N1,3”PS: R1=PS, R2=PS; N1,3”MS: R1=H, R2=Z; N3”BZ: R1=H, R2=BZ; N3”MS: R1=H, R2=MS; N3”PS: R1=H, R2=PS. (C) Experimental paradigm using cochleae from P4 rats to assess ototoxicity of sisomicin and its derivatives in vitro. AG, aminoglycoside. (D) Representative micrograph of the basal turn of undamaged, cultured cochleae, showing myosin VIIa–expressing outer and inner hair cells (OHC and IHC). (E) Sisomicin-treated (200 μM) cochleae showing dramatic loss of outer hair cells. (F) Hair cells were preserved in cochleae cultured with N1MS (200 μM). (G) Hair cell survival (normalized to undamaged, cultured cochleae) in cochleae (divided into 3 regions [base, middle, and apex]) treated with sisomicin or its derivatives (all 200 μM). Sisomicin caused a basal-apical gradient of hair cell loss, whereas treatment with each of the 9 sisomicin derivatives caused less hair cell loss. (H) Dose-response analyses comparing dosage of sisomicin and N1MS treatment to hair cell loss in the basal turn of the cochlea. Sigmoidal best fits estimated Ks of sisomicin and N1MS to be 100 μM and 1.7 mM, respectively. Data are shown as average ± SEM. n = 4–10 for G and H. Scale bar: 25 μm.
commercially available at high purity (>98%) as compared with gentamicin. We selected 3 moieties (methylsulfonyl [MS], phenyl-sulfonyl [PS], and benzoyl [BZ]) to modify these 2 amine groups (1 and 3′) (Figure 1B and Supplemental Figure 1B), which were predicted by X-ray crystallography as dispensable sites for the bacterial ribosome binding-dependent antimicrobial effects of aminoglycosides (25). These functional groups were conjugated to the 1 amine group (N1MS, N1PS, N1BZ), 3′ amine group (N3′MS, N3′PS, N3′BZ), or both the 1 and 3′ amine groups (N1,3′MS, N1,3′PS, N1,3′BZ) of sisomicin (Figure 1B, Supplemental Figure 1C, and Supplemental Figure 2). The chemical synthetic schemes are detailed in Supplemental Figure 1 and ref. 32).

Like gentamicin, sisomicin (200 μM for 1 hour) caused a basal-apical gradient of hair cell loss in in rat cochlear cultures (Figure 1, C–H, and Supplemental Table 1). At the molar equivalent of the parent compound sisomicin (200 μM), all 9 new sisomicin derivatives induced markedly less hair cell loss, with 4 compounds showing almost no hair cell toxicity (Figure 1G and Supplemental Table 1). Conjugation with the MS moiety was more effective than that with either the PS or BZ structures in ameliorating ototoxicity (Supplemental Figure 3, A–C), and all 3 modifications of the sisomicin backbone with the MS moiety eliminated ototoxicity (Supplemental Figure 3, D–F). Dose-response experiments (drug exposure for 1 hour, as above) showed that N1MS (>95% pure, Supplemental Figure 2) is 17 times less toxic than sisomicin (98% pure, \( K_0 = 100 \pm 2 \mu M \) and 1.7 ± 0.2 mM, respectively; Figure 1H and Supplemental Table 2). These data suggest that specific modification of aminoglycosides effectively reduced toxicity against hair cells in vitro.

**Novel aminoglycoside derivatives show antibacterial activities in vitro.** Enterobacteriaceae rank among the most frequently isolated organisms from patients (33). Based on this, we next tested the antimicrobial activities of sisomicin and its derivatives against *E. coli* in vitro. Sisomicin and 2 sisomicin derivatives (N1MS and N1PS) showed comparable minimal inhibitory and bactericidal concentrations (using a concentration of <4 μg/ml to define antimicrobial activity; ref. 34 and Figure 2). All 6 compounds modified at the 3′ amine site showed diminished antimicrobial effects (N3′MS, N3′PS, N3′BZ, N1,3′MS, N1,3′PS, N1,3′BZ; Figure 2).

Because N1MS displayed the most favorable antibacterial activity-ototoxicity profile, it was further tested against clinical isolates of *E. coli*, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus. Similar to sisomicin, gentamicin, and tobramycin, N1MS effectively suppressed growth of most *E. coli* strains (9 of 10), including all 3 extended spectrum β-lactamase-producing (ESBL-producing) strains (Figure 3A), which are multidrug resistant and known to be associated with high rates of patient mortality (35, 36). N1MS inhibited 8 of 10 *K. pneumoniae* strains (including 3 of 5 ESBL-producers), whereas sisomicin was active against 6 of 10 strains (1 of 5 ESBL producers; Figure 3B). Compared with sisomicin, N1MS showed diminished activities against *P. aeruginosa* and *S. aureus* strains (\( P < 0.05 \) for both; Figure 3, C and D). While modifying the 3′ amine group abolished antibacterial activities of all 6 sisomicin derivatives (Figure 2), 3 of 6 (N3′PS, N3′PS, N1,3′BZ) compounds retained some ototoxic effects (Supplemental Figure 3). Conversely, modifying the 1 amine alone reduced the spectrum of antibacterial effects; enhanced activity against *E. coli* and *K. pneumoniae*, consistent with previous results on the aminoglycoside apramycin (16). However, the findings that N1MS showed decreased toxicity against hair cells (17 times less ototoxic), *P. aeruginosa* species (22 times less ototoxic), and *S. aureus* species (18 times less ototoxic) suggest that such dissociation may be species specific. Whether loss of antibacterial activity results from decreased entry into bacteria (2) and/or diminished interaction with bacterial ribosomes remains to be determined.

**Novel aminoglycoside shows diminished entry via hair cell MET channels.** Aminoglycosides are permeant blockers of the hair cell MET channels (10, 24, 27). To assess aminoglycoside trafficking across MET channels, electrophysiological measurements of rat cochlear hair cells were performed in vitro. As expected, sisomicin (100 μM) reduced inward currents elicited by mechanical stimulation (Figure 4A). In comparison, current amplitudes in the presence of an identical concentration of N1MS were larger, indicating that N1MS acted as a lower affinity blocker for the MET channels than sisomicin.

Furthermore, voltage clamping of hair cells showed decreased inward and outward currents in the presence of sisomicin or N1MS across all voltages tested (Figure 4, A and B). The nonlinear voltage-current relationships after drug treatment (sisomicin or N1MS) suggest that both drugs acted as permeant blockers, whose ability to reduce MET channel currents (and thus block the channel) was diminished at the most negative and positive holding potentials. Dose-response experiments at a holding potential of −80 mV...
showed that drug concentrations blocking 50% of MET channel currents were lower for sisomicin than N1MS (Figure 4C). Likewise, at the other negative holding potentials examined, the elevated thresholds in auditory brainstem responses (ABRs) and distortion product otoacoustic emissions (DPOAEs) 1 and 5–6 weeks later (Figure 5, C, E, and F). In contrast, we detected no significant threshold shifts in ABR and DPOAE measurements, except a shift from 8 to 17 dB at the 2 highest frequencies, 1 and 5–6 weeks after N1MS treatment (Figure 5, D–F).

Surface preparation of cochleae from sisomicin-treated mice displayed extensive outer hair cell loss in the middle and basal turns (16.9% ± 10.1% and 11.1% ± 10.5% of saline-treated controls, P < 0.001 for both; n = 9 mice; Figure 6, A and B, Supplemental Table 3), corresponding to loss of auditory function in those animals. Conversely, cochleae from N1MS-treated animals showed substantially more hair cells than sisomicin-treated animals, and thus less toxicity, 1 week and 5–6 weeks after treatment (Supplemental Table 3), consistent with their auditory measurements, which were comparable to those of saline-injected animals (Figure 5, E and F).

To rule out collateral toxicity by sisomicin and N1MS outside the auditory system, 35 different types of organs were examined 3 days after drug administration. Among 5 sisomicin-treated animals, acute renal tubular epithelial degeneration was detected in 2 animals, whereas no tissue toxicity was detected in any of the 10 N1MS-treated animals (Supplemental Table 4). Moreover, we performed dose-response experiments in vivo to determine drug doses that induced animal death and found that sisomicin was lethal at lower doses than N1MS (LD50: 200 ± 2 mg/kg and 544 ± 7 mg/kg, respectively; Supplemental Figure 4). Based on this, we tested the effects of a higher sublethal dose of N1MS and combined it with loop diuretic challenge (400 mg/kg N1MS and 300 mg/kg furosemide). While sisomicin caused ~100% animal mortality at this dose, >95% N1MS-treated animals survived for over a month under these conditions. After treatment with N1MS at this higher dose, there were marked ABR and DPOAE threshold shifts with cor-

**Figure 3. Sisomicin and its novel derivatives inhibit growth of different bacterial species.** (A) Minimal inhibitory concentrations for N1MS, sisomicin, gentamicin, and tobramycin against 10 clinical isolates of *E. coli* showed that all 4 compounds inhibited growth of most strains. Asterisks indicate ESBL-producing strains. MIC50 and MIC90: sisomicin = 1 and >32 μg/ml; N1MS = 1 and 2 μg/ml; gentamicin = 0.5 and >32 μg/ml; tobramycin = 1 and 4 μg/ml, respectively. (B) Growth of most *K. pneumoniae* strains, including some ESBL-producing ones (asterisks), were inhibited by N1MS, whereas sisomicin, gentamicin, and tobramycin showed robust activities predominantly against non-ESBL-producing strains. MIC50 and MIC90: sisomicin = 1 and >32 μg/ml; N1MS = 4 and 64 μg/ml; gentamicin = 0.5 and 64 μg/ml; tobramycin = 0.5 and 32 μg/ml, respectively. (C) Sisomicin, gentamicin, and tobramycin inhibited growth of most *P. aeruginosa* strains, including drug-resistant strains (asterisks). N9744 is resistant to ciprofloxacin, N9750 is resistant to imipenem, and N9923 and N9749 are multidrug resistant. N1MS was inactive against most *P. aeruginosa* strains. MIC50 and MIC90: sisomicin = 0.5 and 8 μg/ml; N1MS = 16 and 64 μg/ml; gentamicin = 2 and 16 μg/ml; tobramycin = 0.5 and 4 μg/ml, respectively. (D) Growth of most *S. aureus* strains was suppressed by sisomicin, gentamicin, and tobramycin but not N1MS treatment. Asterisks indicate methicillin resistant strains. MIC50 and MIC90: sisomicin = 0.25 and 0.5 μg/ml; N1MS = 8 and 8 μg/ml; gentamicin = 0.5 and 0.5 μg/ml; tobramycin = 0.5 and 0.5 μg/ml, respectively. Each bar represents one experiment (n = 1).
Novel aminoglycosides eradicate urinary tract infection. *E. coli* is the most common pathogen causing urinary tract infections (38). To test whether N1MS is effective against urinary tract infections, we inoculated mouse urinary tracts with a uropathogenic strain of *E. coli* (39) followed by treatment with 5 sequential injections of sisomicin or N1MS (Figure 7A). In comparison with saline-injected controls, from which serially collected urine consistently yielded high titers of *E. coli*, both sisomicin and N1MS effectively eliminated bacteria from urine collected 1, 4, and 6 days after inoculation (Figure 7, B–D). All 3 concentrations of N1MS (25, 125, and 625 μg at 5 doses per 20- to 25-g animal) effectively suppressed bacteriuria (Figure 7, B–D). Moreover, bladder and kidney homogenates collected on day 6 demonstrated that both sisomicin and N1MS reduced bacterial titers in urinary tract issues (Figure 7, E and F). One week after treatment, N1MS- and sisomicin-treated mice exhibited normal ABR and DPOAE waveforms and thresholds and also normal serum creatinine levels (625 μg for both; Supplemental Figure 5). In summary, these results indicate that N1MS is effective at eliminating *E. coli*-mediated urinary tract infection, without compromising auditory and kidney functions.

**Discussion**

Aminoglycosides are potent antibiotics that are actively used worldwide, with ototoxicity being the major dose-limiting side effect. Our study uses a novel chemical synthetic approach for alleviating aminoglycoside ototoxicity while preserving anti-
bacterial activity. We modified the aminoglycoside compound based on the notion that hindering aminoglycoside entry via hair cell MET channel prevents ototoxicity (9, 20). The design was based on the biophysical properties of the MET channel (24, 26), whose candidate molecular compositions are still being elucidated (22, 40–42). Nonetheless, electrochemical gradients drive cations through the MET channel; therefore, the conversion of basic amine sites of aminoglycosides into carboxamides or sulfonamides renders them nonbasic (less positively charged) and was predicted to decrease drug entry and subsequent toxicity. Our paradigm produced sisomicin derivatives exhibiting diminished in vitro toxicity relative to the parent compound sisomicin, with the lead compound N1MS less capable of crossing the MET channels than sisomicin. While the electrophysiological measurements were made in vitro to assess drug entry across the MET channel, the electrochemical gradient present in vivo in the intact cochlea is substantially larger. This difference may in part account for the 17-fold decreased ototoxicity in vitro and 2.3-fold decreased ototoxicity in vivo between N1MS and sisomicin. As the MET channel pore size is estimated at 1.25 ± 0.08 nm at its narrowest segment (24), it is possible that the larger sizes of sisomicin derivatives may also impede drug entry. However, the effects of compound dimension are likely limited, as the moieties added were relatively small. Thus, future experiments using bulkier moieties may further delineate the relationships among aminoglycoside dimensions and drug entry and ototoxicity.

A rich body of literature supports the hypothesis that oxidative stress mediates aminoglycoside-induced hair cell degeneration (12, 43), yet the initial events that generate reactive oxygen species are poorly understood. Building upon the knowledge that the human mitochondrial mutation A1555G (GenBank accession no. NC 012920) increases the risk of hearing loss after aminoglycoside treatment (44), recent work has revealed the potential roles of mitochondrial stress in aminoglycoside ototoxicity (16, 45). In particular, work on apramycin, a structurally unique aminoglycoside used in veterinary medicine, suggests that its differential antiribosomal activities against eukaryotic cells versus bacteria contribute to its low ototoxic potential. Moreover, recent work suggests that aminoglycosides induce hair cell toxicity by causing ribotoxic stress and in turn inhibit cytoplasmic protein synthesis (46). While our data support the conclusion that decreased drug entry via MET channels underlies diminished aminoglycoside ototoxicity, we did not determine whether sisomicin and sisomicin derivatives differentially bind eukaryotic and bacterial ribosomes, induce ribotoxic stress, or inhibit protein synthesis in hair cells. One or all of these mechanisms may have also contributed to N1MS’s decreased ototoxicity.

Because aminoglycosides can provide broad coverage of gram-negative organisms, they are widely used when the offending organisms are unknown, such as in the setting of neonatal sepsis or peritonitis (47, 48). Additionally, aminoglycosides are clinically indicated for treating pneumonia caused by *P. aeruginosa* and urinary tract infection caused by *E. coli* (2). Differential binding affinities for

---

**Figure 5. Modified aminoglycoside prevents hearing loss.** (A) Schematic of drug treatment to deafen 30-day-old CBA/CaJ mice. (B) Representative ABR tracings in a saline-treated mice showing a 30 dB SPL threshold at 23 kHz. (C) Sisomicin-treated (175 mg/kg) mice showed no detectable responses. (D) In contrast, mice administered with N1MS (175 mg/kg) exhibited normal auditory responses (thresholds = 30 dB SPL). (E and F) ABRs and DPOAEs of animals administered saline 1 week prior (magenta), 175 mg/kg sisomicin 1 week prior (black), 175 mg/kg N1MS 1 week prior (red), 175 mg/kg sisomicin 5–6 weeks prior (green), 175 mg/kg N1MS 5 to 6 weeks prior (blue), and 400 mg/kg N1MS 1 week prior (cyan). Sisomicin-treated animals had elevated ABR and DPOAE thresholds in comparison to saline-treated animals, whereas N1MS-treated animals had robust ABR and DPOAE signals 1 and 5–6 weeks after treatment. High-dose sisomicin treatment was lethal (Supplemental Figure 5). High-dose N1MS treatment caused elevated ABR and DPOAE thresholds. Data are shown as average ± SEM. For E and F, n = 57 for saline control; n = 9–14 for other groups.
bacterial ribosomes may contribute to the selectivity of individual aminoglycosides (49, 50). The findings that modification at the 3′ amine site reduced antibacterial activity and that N1MS is selectively active against E. coli and K. pneumoniae are consistent with such a structure-activity relationship. Although N1MS shows decreased activity against P. aeruginosa and S. aureus, it is conceivable that a higher dose of the less ototoxic N1MS may be used to overcome its diminished antimicrobial activity against these organisms. The effects on nephrotoxicity of such a regimen will need to be elucidated. Alternatively, modifications at the 1 amine site may further separate ototoxicity from antimicrobial activity and restore efficacy against a wide spectrum of bacteria. Thus, future studies should further delineate N1MS’s therapeutic window and the structural activity relationships of additional aminoglycoside derivatives.

Aminoglycoside-induced vestibulotoxicity presents both as a side effect of treatment for systemic infection (4) and as an intended therapeutic effect, such as for Meniere’s disease (51). However, the current study did not directly compare whether sisomicin and its derivatives differ in their vestibular hair cell toxicity; such a comparison may help determine the candidacy of aminoglycoside derivatives as clinical therapeutics.

As ototoxicity limits both the dose and duration of aminoglycoside treatment, our study provides proof-of-concept data supporting targeted modification of aminoglycosides as an effective strategy to prevent iatrogenic hearing loss. Future studies modifying other aminoglycoside compounds may help generate a family of aminoglycoside antibiotics with minimized risk of ototoxicity and thus add to the armamentarium of antibiotics.

Figure 6. Modified aminoglycoside prevents sensory cell loss in vivo. (A) Whole-mount preparation showing myosin VIIa–positive hair cells in the cochlear basal turn. Three rows of outer hair cells and a single row of inner hair cells are present in saline-treated animals. (B) Sisomicin treatment caused outer hair cell loss. (C) Hair cells are preserved in N1MS-treated animals. (D) Quantification of myosin VIIa–positive outer hair cells shows dramatic cell loss (as percentages of saline-treated controls) in a basal-apical gradient after sisomicin treatment, whereas N1MS treatment preserved markedly more hair cells. Treatment with 400 mg/kg N1MS produced hair cell loss. Data are shown as average ± SEM. For D, n = 57 for saline control; n = 9–14 for other groups. Scale bar: 25 μm.

Methods

Cochlear cultures. Cochlear tissues were harvested from P4 rats and cultured as previously described (9). Sterile dissection was first performed in Hank’s balanced salt solution or Leibovitz’s L-15 medium (GIBCO, Life Technologies Corp.). Harvested tissues were cultured in Dulbecco’s Modified Eagle Medium/F-12 medium containing 10% heat-inactivated fetal bovine serum (both GIBCO) and 0.01% ampicillin (Sigma-Aldrich) overnight (37°C and 5% CO2) before aminoglycoside treatment. Drug treatment lasted 1 hour, after which organs were incubated in aminoglycoside-free media for an additional 48 hours. Sisomicin sulfate (98% pure, OChem), gentamicin, and tobramycin were used (Sigma-Aldrich). Sisomicin derivatives were synthesized by Nanosyn Inc. (see below).

Chemical synthesis. The modified sisomicin derivatives were prepared from sisomicin sulfate, which was first converted into N-6′-p-nitrobenzoyloxycarbonyl-N-2′,N-3-bis-t-butylloxycarbonyl sisomicin using published procedures (refs. 31, 32, and Supplemental Figure 1A). Because N1 has been demonstrated to react preferentially over N3′ with acid chlorides (31), sulfonylation or benzoylation occurs selectively at the N1 amine, while both N1 and N3′ are functionalized with the use of excess reagent (Supplemental Figure 1A). For the monofunctionalization of N3′, N-6′-p-nitrobenzoyloxycarbonyl-N-2′,N-3-bis-t-butylloxycarbonyl sisomicin was further protected as the N-1-α-nitrobenzenesulfonyl derivative (Supplemental Figure 1B), followed by sulfonylation or benzoylation of N3′. Last, deprotection of the functionalized molecules was done using established procedures (31, 52). The final products were purified by preparative high-pressure liquid chromatography (not shown), with their purities determined by mass spectrometry (evaporative light scattering detector) (N1BZ = 100%, N1MS = 99.0%, N1PS = 96.4%, N1,3′BZ = 99.0%, N1,3′MS = 99.5%, N1,3′PS = 98.9%, N3′BZ = 99.3%, N3′MS = 99.0%, and N3′PS = 99.3%). The structural assignments were also confirmed using a Thermo Ultimate 3000 RS UHPLC system.

Electrophysiology. P7–9 rat cochlear explants were prepared and whole cell patch recordings were obtained from inner hair cells as previously described (19, 53). The pipette solution contained 125 mM CsCl, 3.5 mM MgCl2, 5 mM ATP, 5 mM creatine phosphate, 10 mM HEPES, 1 mM EGTA, 2 mM ascorbate (pH = 7.2), 280–285 mOsm per kg water, while the extracellular solution contained 140 mM NaCl, 2 mM KCl, 2 mM CaCl2, 2 mM MgCl2, 10 mM HEPES, 6 mM glucose, 2 mM pyruvate, 2 mM ascorbate (pH = 7.4), 300–310 mOsm per kg water. A glass probe affixed to a piezoelectric stack was used to mechanically stimulate the hair bundles; stimulus amplitudes were selected to provide the maximal positive and negative response.

Immunohistochemistry. As previously described (9), cultured tissues were fixed with 4% paraformaldehyde in PBS at pH 7.4 for 20 minutes at room temperature. For adult cochlear tissues, fixative was gently infused through an apical bony window and the oval window and then incubated in fixative for 45 minutes at room temperature. EDTA was applied to tissues (500 mM for 30 to 40 minutes), before washing with PBS 3 times. Bony capsules of cochleae were microdissected away, and stria vascularis and tectorial membranes were removed to expose the organ of Corti.

Tissues were then immersed in a blocking solution containing 5% bovine serum albumin and Triton-X 1% in PBS for 1 hour. Samples were incubated with anti-mycosin VIIa antibody (1:1,000; Proteus Biosci-
Inhibitory concentration (MIC). To determine antibiotic efficacy, we used a bacterial pellet at the bottom of the tube) was defined as the minimum biotic concentration sufficient to inhibit bacterial growth (an absence of bacterial growth during MIC assays onto Müller-Hinton agar (Becton Dickerson) at 37°C overnight. The lowest antibiotic concentration of <4 μg/ml as the criteria, as defined for gentamicin by the Clinical and Laboratory Standards Institute (34).

**Microscopic imaging and quantification.** Tissues were imaged using a confocal laser scanning microscope (Zeiss LSM 5 Pascal AxioVert 200M, Carl Zeiss AG). The cochlea was divided into 3 regions (base, middle, and apex), and 1 or 2 areas per region were imaged. In every area, outer hair cells were counted.

**Bacterial culture.** Antimicrobial activity was measured by incubating serial dilutions of sisomicin or derivatives with a constant bacterial inoculum. *E. coli* XL blue (Agilent Technologies) was incubated in 3 ml Müller-Hinton broth (Becton Dickerson) at 37°C overnight to generate static phase cultures. The following day, incubation tubes were inoculated with 10^6 CFU bacteria. Serial 2-fold dilutions of the aminoglycoside compounds (0.03–64 μg/ml) were added to 2 ml Müller-Hinton broth (54). The inoculated tubes were incubated at 37°C overnight. The lowest antibiotic concentration sufficient to inhibit bacterial growth (an absence of bacterial growth) was defined as the minimum inhibitory concentration (MIC). To determine antibiotic efficacy, we used an antibiotic concentration of <4 μg/ml as the criteria, as defined for gentamicin by the Clinical and Laboratory Standards Institute (34).

**Mouse model of urinary tract infection.** Procedures were performed as previously described (39). Briefly, type I pili expression was induced in the uropathogenic *E. coli* strain UTI89 by inoculating bacteria into the bladders of female 7- to 8-week-old CBA/CaJ mice by transurethral catheterization. For drug treatment, infected mice were injected subcutaneously with sisomicin or N1MS (25–625 μg/25 g dissolved in 100 μl of PBS) every 2 hours for a total of 5 injections after UTI89 infection.

Aseptically excised bladders and kidneys were minced and homogenized in 400 μl sterile PBS. Freshly collected urine or tissue homogenates were then serially diluted 10^- to 1,000-fold. Twenty-five μl of each dilution was plated onto MacConkey agar plates. CFUs were counted after 24 hours of incubation at 37°C.

To determine the minimum bactericidal concentration (MBC) of the aminoglycoside compounds, we streaked out 50 μl from aminoglycoside-containing, bacteria-inoculated tubes that exhibited no bacterial growth. Whereas tissues feature high bacterial titers in the absence of antibiotic treatment, both sisomicin and N1MS reduced colony formation, especially at the higher doses.

**Figure 7. N1MS eradicates urinary tract infection in vivo.**

(A) Schematic of *E. coli* infection of the mouse urinary tract and treatment with sisomicin or N1MS. The uropathogenic *E. coli* strain UTI89 was inoculated into bladders of 7- to 8-week-old CBA/CaJ mice. (B–D) Scatter plots show that when animals received no antibiotic treatment (Abx) (black), urine collected on day 1, 4, or 6 featured high bacterial titers. While low doses (25 and 125 μg) of sisomicin (red) and N1MS (green) reduced bacterial growth, high doses of both drugs (625 μg) effectively prevented bacterial growth. (E and F) Homogenates of bladders and kidneys from mice whose bladders were inoculated with *E. coli* were examined for bacterial growth. Whereas tissues feature high bacterial titers in the absence of antibiotic treatment, both sisomicin and N1MS reduced colony formation, especially at the higher doses.

$n = 10$ for B–F.
overnight incubation at 37°C. The limits of detection were 4,000 CFU/ml for urine and 160 CFU per bladder. To determine creatinine levels, 25 μl of serum was collected from each mouse and sent to the Diagnostic Laboratory of Veterinary Service Center at Stanford University.

Auditory measurements. ABRs and DPOAEs were measured as previously described with custom hardware based around a data acquisition board (PCOe-6251, National Instruments) driven by software written in MATLAB (Mathworks) (55, 56). Briefly, mice were sedated with a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg). ABR signals were measured from a needle electrode positioned inferior to the tympanic bulla, referenced to an electrode placed at the vertex of the head, and a ground electrode was placed at the hind leg. Tone burst stimuli were delivered with frequencies ranging from 4 to 64 kHz (4, 8, 16, 32, 64 kHz) and sound intensities raised from 10 to 80 dB sound pressure level (SPL) in 10-dB steps. At each frequency and sound level, 260 trials were sampled and averaged.

DPOAEs were measured by a probe tip microphone in the external auditory canal. The sound stimuli were two 1-second sine wave tones of differing frequencies (F₂ = 1.22 × F₁). F₂ was varied from 4 to 46 kHz, and the intensities of 2 tones were from 20 to 80 dB SPL with 10-dB steps. The amplitude of the cubic distortion product was measured at 2 × F₁-F₂. The threshold at each frequency was calculated to be when the DPOAE was >5 dB SPL and 2 SDs above the noise level. For statistical analyses of both ABR and DPOAE responses, a lack of response is designated 80 dB SPL.

Histology of organs (necropsy). All procedures were performed by a board-certified veterinary pathologist at the Diagnostic Laboratory of Veterinary Service Center at Stanford University. First, a complete gross examination of organs and tissues was performed. A comprehensive list of organs and tissues was sampled (Supplemental Table 4), and gross examination of organs and tissues was performed. A complete necropsy was performed by a board-certified veterinary pathologist at the Diagnostic Laboratory of Veterinary Service Center at Stanford University. First, a complete gross examination of organs and tissues was performed. A comprehensive list of organs and tissues was sampled (Supplemental Table 4), and gross examination of organs and tissues was performed. After 48 to 72 hours of formalin fixation, the organs and tissues were trimmed and processed routinely for light microscopic examination. Specifically, 4-micron thick, hematoxylin and eosin–stained tissue sections were evaluated using an Olympus BX-41 microscope (Olympus).